Featuring an interview with Dr Philip A Philip, including the following topics:
- Comprehensive biomarker analysis for patients diagnosed with colorectal cancer (CRC) (0:00)
- Selection of first-line therapy for patients with metastatic CRC (mCRC) (7:51)
- Therapeutic options for patients with HER2-positive mCRC (10:10)
- Patient selection for regorafenib and/or TAS-102 with or without bevacizumab for mCRC (16:57)
- Selection and sequencing of therapeutic options for patients with unresectable or metastatic gastric or gastroesophageal junction cancer (19:52)
- Current and emerging immune checkpoint inhibitor-based combinations for hepatocellular carcinoma (24:51)
- First- and later-line therapy for patients with advanced biliary tract cancers (33:17)
- Activity of NALIRIFOX (liposomal irinotecan/oxaliplatin/leucovorin/fluorouracil) for treatment-naïve metastatic pancreatic cancer (36:12)
CME information and select publications
Research To Practice | Oncology Videos